Exelixis Inc (EXEL) Operating Margin
- Operating margin · 12 months: Value 39.88%; Formula and calculation Operating income / revenue. Period ending 2026-07-03..
Operating margin
Overview →Financial period ending 2026-07-03; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 39.88% | Operating income / revenue. Period ending 2026-07-03. $971.51M ÷ $2.44B × 100 ≈ 39.88% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 971.51M USD | Operating Income (Loss) |
| Revenue | 2.44B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 85.67M USD | Cost of Goods and Services Sold |
| Research and development | 824.32M USD | Research and Development Expense |
| Selling, general and administration | 533.92M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-07-03 | $971.51M | $2.44B | $85.67M | $824.32M | $533.92M | 39.88% |
| 2026-04-03 | $936.67M | $2.38B | $84.48M | $812.68M | $521.15M | 39.43% |
| 2026-01-02 | $872.19M | $2.32B | $83.70M | $825.00M | $518.73M | 37.59% |
| 2025-10-03 | $800.18M | $2.29B | $77.18M | $860.75M | $530.03M | 34.97% |
| 2025-07-04 | $699.72M | $2.23B | $75.94M | $884.16M | $518.17M | 31.38% |
| 2025-04-04 | $762.01M | $2.30B | $74.13M | $894.95M | $515.33M | 33.15% |
| 2025-01-03 | $604.62M | $2.17B | $76.22M | $910.41M | $492.13M | 27.88% |
| 2024-09-27 | $523.20M | $2.08B | $78.00M | $906.08M | $489.24M | 25.13% |
| 2024-06-28 | $369.54M | $2.01B | $79.45M | $1.02B | $515.58M | 18.35% |
| 2024-03-29 | $171.52M | $1.85B | $79.49M | $1.04B | $525.29M | 9.29% |
| 2023-12-29 | $170.88M | $1.83B | $72.55M | $1.04B | $542.71M | 9.34% |
| 2023-09-29 | $41.02M | $1.77B | $66.71M | $1.14B | $530.51M | 2.31% |
| 2023-06-30 | $141.22M | $1.71B | $63.24M | $1.00B | $507.35M | 8.24% |
| 2023-03-31 | $147.07M | $1.66B | $59.02M | $969.39M | $488.39M | 8.84% |
| 2022-12-30 | $201.48M | $1.61B | $57.91M | $891.81M | $459.86M | 12.51% |
| 2022-09-30 | $366.21M | $1.64B | $54.91M | $777.26M | $439.92M | 22.35% |
| 2022-07-01 | $335.21M | $1.55B | $51.48M | $741.79M | $426.49M | 21.56% |
| 2022-04-01 | $374.52M | $1.52B | $52.88M | $691.10M | $402.23M | 24.63% |
| 2021-12-31 | $286.67M | $1.43B | $52.87M | $693.72M | $401.71M | 19.98% |
| 2021-10-01 | $194.32M | $1.25B | $48.99M | $625.73M | $384.84M | 15.50% |
| 2021-07-02 | $100.12M | $1.16B | $45.84M | $639.12M | $371.47M | 8.66% |
| 2021-04-02 | $52.64M | $1.03B | $40.18M | $605.26M | $332.77M | 5.11% |
| 2021-01-01 | $110.06M | $987.54M | $36.27M | $547.85M | $293.36M | 11.14% |
| 2020-10-02 | $163.08M | $957.80M | $37.76M | $488.02M | $268.94M | 17.03% |
| 2020-07-03 | $321.26M | $998.41M | $36.57M | $408.55M | $232.02M | 32.18% |
| 2020-04-03 | $337.72M | $979.20M | $34.88M | $375.55M | $231.05M | 34.49% |
| 2020-01-03 | $369.47M | $967.77M | $33.10M | $336.96M | $228.24M | 38.18% |
| 2019-09-27 | $403.76M | $956.07M | $29.93M | $299.79M | $222.59M | 42.23% |
| 2019-06-28 | $413.33M | $909.76M | $29.75M | $247.23M | $219.45M | 45.43% |
| 2019-03-29 | $407.11M | $855.59M | $28.21M | $207.79M | $212.49M | 47.58% |
| 2018-12-28 | $438.86M | $853.83M | $26.35M | $182.26M | $206.37M | 51.40% |
| 2018-09-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-28 | $364.68M | $745.30M | (m) | $157.19M | $200.27M | 48.93% |
| 2018-06-29 | $320.69M | $672.41M | (m) | $140.99M | $190.28M | 47.69% |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-30 | $262.03M | $583.94M | (m) | $126.72M | $177.72M | 44.87% |
| 2017-12-29 | $165.91M | $452.48M | (m) | $112.17M | $159.36M | 36.67% |
| 2017-09-30 | $167.36M | $409.99M | (m) | $103.77M | $126.12M | 40.82% |
| 2017-09-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $93.45M | $319.67M | (m) | $95.48M | $120.45M | 29.23% |
| 2017-03-31 | $41.20M | $256.91M | (m) | $90.25M | $115.55M | 16.04% |
| 2016-12-31 | $-28.12M | $191.45M | (m) | $95.97M | $116.14M | -14.69% |
| 2016-12-30 | $-28.12M | $191.45M | (m) | $95.97M | $116.14M | -14.69% |
| 2016-09-30 | $-98.61M | $123.81M | (m) | $95.64M | $120.29M | -79.64% |
| 2016-07-01 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-141.65M | $71.47M | (m) | $101.47M | $105.67M | -198.20% |
| 2016-04-01 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-147.80M | $43.21M | (m) | $103.00M | $82.63M | -342.03% |
| 2016-01-01 | $-121.42M | $37.17M | (m) | $96.35M | $57.30M | -326.65% |
| 2015-12-31 | $-121.42M | $37.17M | (m) | $96.35M | $57.30M | -326.65% |
| 2015-09-30 | $-136.03M | $34.59M | (m) | $112.53M | $49.93M | -393.30% |
| 2015-06-30 | $-151.82M | (m) | (m) | $130.07M | $41.99M | (m) |
| 2015-03-31 | $-182.23M | (m) | (m) | $156.54M | $45.67M | (m) |
| 2014-12-31 | $-224.46M | $25.11M | (m) | $189.10M | $50.83M | -893.86% |
| 2014-09-30 | $-237.76M | $22.11M | (m) | $199.05M | $54.70M | -1075.61% |
| 2014-06-30 | $-242.10M | $21.28M | (m) | $202.77M | $58.39M | -1137.70% |
| 2014-03-31 | $-231.71M | $26.57M | (m) | $200.88M | $55.10M | -871.94% |
| 2013-12-31 | $-200.73M | $31.34M | (m) | $178.76M | $50.96M | -640.54% |
| 2013-09-30 | $-183.19M | $34.80M | (m) | $161.66M | (m) | -526.34% |
| 2013-06-30 | $-152.72M | $42.65M | (m) | $144.98M | (m) | -358.07% |
| 2013-03-31 | $-134.15M | $38.61M | (m) | $128.52M | (m) | -347.46% |
| 2012-12-31 | $-122.44M | $47.45M | (m) | $128.88M | (m) | -258.03% |
| 2012-09-30 | $-28.89M | $132.94M | (m) | $127.16M | (m) | -21.73% |
| 2012-06-30 | $76.25M | $247.90M | (m) | $133.95M | (m) | 30.76% |
| 2012-03-31 | $90.97M | $272.25M | (m) | $144.24M | (m) | 33.41% |
| 2011-12-31 | $89.53M | $289.64M | (m) | $156.84M | (m) | 30.91% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $178.74M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-91.40M | $185.04M | (m) | $210.68M | (m) | -49.39% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-121.91M | $151.76M | (m) | $234.70M | (m) | -80.33% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |